Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J
Clin Cancer Res. 2012 18 (12): 3414-27

PMID: 22510349 · DOI:10.1158/1078-0432.CCR-11-3369

MeSH Terms (21)

Adult Aged Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Benzenesulfonates Biomarkers, Tumor Deoxycytidine Erlotinib Hydrochloride Female Humans Male Middle Aged Neoplasms Niacinamide Panitumumab Phenylurea Compounds Pyridines Quinazolines Receptor, IGF Type 1 Sorafenib

Connections (1)

This publication is referenced by other Labnodes entities: